| Welcome to FierceLifeSci Weekly Digest, your Friday roundup of the biggest and most popular stories from each of our publications. | |
|
Top Stories Of The Week Thursday, June 30, 2016 Tesaro posted stellar Phase III results yesterday for its PARP inhibitor in ovarian cancer. But following on its good vibes have been other PARP R&D players that all saw their shares jump. The results could make a major difference to the acquisition hopes of Sanofi and Medivation while pulling Clovis out of its shares rut. Read more from FierceBiotech Monday, June 27, 2016 Medtronic will add a heart failure implant and pipeline products in its $1.1 billion acquisition of HeartWare. The deal will accelerate the development of HeartWare's products and round out Medtronic's Cardiac Rhythm & Heart Failure division. Read more from FierceMedicalDevices Monday, June 27, 2016 After a lengthy investigation, "deception on a grand scale" has prompted British marketing watchdogs to suspend Astellas UK, triggering a shake-up at the top of the Japanese drugmaker's European unit. The Prescription Medicines Code of Practice Authority called it "one of the worst cases" it had ever investigated. Read more from FiercePharmaMarketing Wednesday, June 29, 2016 Mouse studies have shown that small doses of an HIV drug boost the brain’s ability to clear cholesterol. Now, a Case Western Reserve University team has identified how the drug works, suggesting it could be effective in delaying or preventing Alzheimer’s disease in humans. Read more from FierceBiotechResearch Monday, June 27, 2016 After getting ensnared in regulatory issues at three of the sterile injectable plants that it bought from Agila Specialties in a $1.75 billion deal, Mylan decided it needed a clean slate at the plant. To get there, it fired workers, hired new employees and started over. Read more from FiercePharmaManufacturing Monday, June 27, 2016 Confidence in the strength of the CRO sector continues apace as Medpace files for a $150 million initial public offering. Read more from FierceCRO Tuesday, June 28, 2016 Pfizer has bet long on biosimilars in China by announcing a $350 million facility, marking a first in Asia and a major new investment in the country. Read more from FiercePharmaAsia Monday, June 27, 2016 France has joined the growing list of countries with aspirations to establish population-scale genome sequencing operations. The plan is to invest approximately $745 million to build a network of sequencing and analysis centers capable of processing the equivalent of 235,000 genomes a year by 2020. Read more from FierceBiotechIT Monday, June 27, 2016 Boehringer Ingelheim and Sanofi are making progress on an asset swap that will make BI a major player in animal health. Read more from FierceAnimalHealth Tuesday, June 28, 2016 Researchers at ITMO University in St. Petersburg, Russia, have developed a magnetically controlled treatment designed to dissolve blood clots. The method looks to be a promising solution to some of the complications associated with enzyme-based thrombolytic drugs. Read more from FierceDrugDelivery Monday, June 27, 2016 Just months after GlaxoSmithKline’s malaria vaccine Mosquirix was given an EMA green light last July, it suffered a setback at the WHO, which recommended that the vaccine be examined in pilot programs before introduction through large immunization campaigns. Now, international vaccine alliance Gavi is stepping in with conditional funding to help the upcoming real-world programs get underway. Read more from FierceVaccines
|
|
